Xing Yurou, Zhao Kejia, Zhang Yi, Wang Yongsheng
Thoracic Oncology Ward, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Department of Thoracic Surgery and Institute of Thoracic Oncology, West China Hospital of Sichuan University, Sichuan University, Chengdu, Sichuan, China.
Front Oncol. 2024 Dec 24;14:1463505. doi: 10.3389/fonc.2024.1463505. eCollection 2024.
The prognosis of primary central nervous system lymphoma (PCNSL) patients is relatively poor, and there is currently no standard treatment plan. Most patients choose high-dose chemotherapy based on methotrexate. While traditional chemotherapy combined with biological therapy has achieved limited results, some patients still do not respond to treatment or cannot tolerate its toxicity and side effects. Bruton's tyrosine kinase (BTK) is a key enzyme in B-cell receptor signaling, and its activation is critical for B-cell survival and proliferation. In recent years, BTK inhibitors have shown great potential in treating lymphomas derived from various B cells because of their strong targeting ability and relatively few side effects. They may also be a reasonable treatment choice for PCNSL. This article reviews the mechanism of action, clinical research, adverse reactions, and other issues of BTK inhibitors in treating PCNSL to provide a reference for individualized treatment of patients with PCNSL.
原发性中枢神经系统淋巴瘤（PCNSL）患者的预后相对较差，目前尚无标准治疗方案。大多数患者选择基于甲氨蝶呤的大剂量化疗。虽然传统化疗联合生物治疗取得的效果有限，但仍有部分患者对治疗无反应或无法耐受其毒性和副作用。布鲁顿酪氨酸激酶（BTK）是B细胞受体信号传导中的关键酶，其激活对B细胞的存活和增殖至关重要。近年来，BTK抑制剂因其强大的靶向能力和相对较少的副作用，在治疗各种B细胞来源的淋巴瘤方面显示出巨大潜力。它们也可能是PCNSL的合理治疗选择。本文综述了BTK抑制剂治疗PCNSL的作用机制、临床研究、不良反应等问题，为PCNSL患者的个体化治疗提供参考。
